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Abstract 
Tumefactive  fibroinflammatory  lesion
(TFIL) is a rare benign tumor in the head and
neck region. We present a case of a 40-year-old
female with a benign but progressive lesion of
the infratemporal fossa, which was diagnosed
as TFIL. Patient responded briefly to a course
of  steroid  treatment  but  eventually  showed
progression and was unresponsive to further
steroids. She was then treated with external
beam radiation to a dose of 60 Gy in 30 frac-
tions. After radiation a slow, gradual decrease
in tumor size was noted over the course of
years  and  she  is  free  of  disease  after  more
than  11  years  of  follow-up.  The  major  long-
term side effect this patient developed was an
expected  unilateral  radiation-induced
retinopathy, due to the close proximity of the
lesion to the orbit. The dilemma of treatment
of benign disease with radiation with potential
long-term  complications  is  discussed  and  a
review of the literature on TFIL is presented.
Introduction
Clinicians are sometimes confronted with a
patient presenting with a malignant-appearing
mass as based on clinical characteristics (size,
location and nature of growth, e.g.infiltrative or
destructive) and details from the medical histo-
ry (fashion of appearance and rate of progres-
sion). Despite this presentation however, the
nature of this mass may be related to a condi-
tion with a benign histological appearance. 
In the medical literature, these lesions have
often been described as inflammatory pseudo-
tumors (IPT),1 however multiple other terms
have been used to describe these, depending
on the site of occurrence, the organ of origin or
the predominant pathologicafeatures, e.g. plas-
ma cell granuloma of the lung,2xanthogranulo-
ma,3 or  histiocytoma.4 Overall,  these  tumors
are rare and difficult to classify because of the
lack of clear diagnostic criteria, leading to the
use of multiple synonyms. In general, they can
be categorized as non-neoplastic, fibroinflam-
matory proliferations.
Within the broad spectrum of IPT’s, a condi-
tion  named  tumefactive  fibroinflammatory
lesion (TFIL) is a rare idiopathic fibroscleros-
ing disorder occurring in the head and neck
region, which has a locally destructive nature
but is characterized by a benign histological
appearance. As this is not a malignancy, there
is no tendency for metastases. However, the
clinical  behavior  with  locally  aggressive
growth and the surgical findings of infiltration
resemble  those  of  an  invasive  malignancy.
Because  of  the  discrepancy  between  the
aggressive  clinical  manifestation  and  the
benign  histological  features,  these  lesions
often pose a dilemma in terms of diagnosing
and treatment. Rice et al.5 first described the
abnormality in 1975 as sclerosing cervicitis. It
was first named tumefactive fibroinflammato-
ry lesion by Wold et al.6 in 1983. The lesions
usually develop in the head and neck region,
although they rarely arise in other areas like
the extremities.7;8Treatment strategies for this
benign  lesion  are  not  well  defined  and  are
based on individual reports, including the use
of  high-dose  steroids,  surgery  and  radiation
treatment, all with varying results. Little infor-
mation is available on the results of radiation
treatment as this has only been the treatment
of choice in a few cases in literature.5;9;10
In this paper we present a case with an infil-
trative lesion in the infratemporal fossa diag-
nosed as TFIL, which appeared to be refractory
to and progressive on steroids and was treated
with definitive radiotherapy. The extent of sur-
gery that would have been required to resect it
was regarded as unacceptable to the treatment
team and the patient, without first considering
other  options.  The  issues  of  difficulties  in
establishing a pathological diagnosis will be
described and we will present a review of the
available literature on TFIL.
Case Report 
Clinical presentation
A previously healthy 40-year-old female pre-
sented  in  1997  at  the  Princess  Margaret
Hospital  with  a  3-4  months  history  of  an
increased swelling in her right temporal area.
She  underwent  initial  investigations  else-
where including plain skull film x-rays and a
bone scan, which did not show any abnormali-
ty. She then developed progressive sensations
of pressure with pulsatile aching in the temple
region  and  also  in  her  right  eye  and  upper
teeth on the right side. There were no com-
plaints  suggestive  of  diplopia,  facial  nerve
paralysis, hearing loss, tinnitus or vertigo. The
lesion  did  not  change  dramatically  in  size
since the first presentation. She did not pres-
ent  any  constitutional  symptoms,  or  any
weight loss. She was a non-smoker and report-
ed no alcohol abuse. There was no history of
radiation exposure. She had a previous history
of tubal pregnancy and a tubal ligation in 1994.
Her family history was positive for a brother
who died at age of 5 secondary to a brain tumor
of indeterminate histology.
On physical examination, an 8ﾥ6 cm hard,
non-tender, fixed mass in the right infratem-
poral fossa was noted, which extended deep to
the zygoma bone into the infratemporal fossa.
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The  overlying  skin  was  mobile  without  any
skin involvement. There were no signs of tris-
mus or proptosis, and cranial nerve examina-
tion  was  normal.  The  reported  symptoms  of
one episode of paraesthesia over her right face
in the V2 and V3 distribution could not be cor-
related with obvious signs of trigeminal nerve
involvement.
Imaging was performed using magnetic reso-
nance  imaging  (MRI).  On  these  a  large  ill-
defined swelling in the right temporal fossa was
noted,  superficially  extending  over  the  right
parotid region, and involving the scalp, superfi-
cial subcutaneous tissues and the temporalis
muscle. The mass was in close proximity to lat-
eral aspect of the right orbit. On T2-weighted
images, increased signal intensity was noted in
the lesion and area of the involved temporal
muscle. The lesion had an intermediate high
signal on T1 and showed clear enhancement
after gadolinium administration. The mass was
measured as 6.0ﾥ2.0ﾥ4.0 cm in the anterior-
posterior,  transverse  and  cranio-caudal  direc-
tions, respectively.
Based on the clinical presentation a differ-
ential  diagnosis  of  rhabdomyosarcoma,
fibrosarcoma  or  fibromatosis  was  made.  To
obtain a histological diagnosis, an incisional
open biopsy was performed. During this proce-
dure,  the  lesion  appeared  as  an  extremely
hard, white, firm mass enveloping the tempo-
ral muscle and it was noted to have become
confluent with the muscles.
Pathology
The mass consisted of a hypocellular lesion
composed of bland fibroblasts and myofibrob-
lasts surrounded by dense eosinophilic colla-
gen extending into striated muscle and adipose
tissue. The mass showed a striking perivascu-
lar infiltrate of small lymphocytes and plasma
cells.  Scattered  plasma  cells,  small  lympho-
cytes, and mast cells were present in the col-
lagenous tissue. No cellular atypia, necrosis, or
mitoses  were  seen  (Figure  1A  and  1B).
Immunohistochemical  stainings  were  per-
formed on the tumor sample and showed that
many  of  the  spindle  cells  were  positive  for
smooth muscle actin (SMA) and muscle specif-
ic actin (MSA) and negative for desmin. Based
on this, at that time the diagnosis of tumefac-
tive fibroinflammatory lesion (TFIL) was made.
For the purpose of this case report, the original
tumor  block  was  retrieved  for  additional
immunohistochemical  stainings.  These  stud-
ies showed that the spindle cells were negative
for CD30, CD34, Alk-1, ʲ-catenin, and epithelial
membrane antigen (EMA) (Figure 1C). These
results confirmed the fibroblastic and myofi-
broblastic phenotype of the spindle cells, con-
sistent with the original diagnosis of TFIL.
Treatment and clinical outcome
In multidisciplinary setting, the treatment
approach was established. A complete thoracic
and abdominal imaging work-up was done to
rule  out  other  manifestations  of  idiopathic
fibrosing  conditions  such  as  retroperitoneal
fibrosis, and this revealed no abnormalities.
Given the extent of disease it was decided to
start with steroid treatment, and reserve radi-
ation treatment for any failure. Based upon the
extent  and  location  of  the  disease,  surgical
management  would  be  associated  with  cos-
metic  and  functional  disabilities,  and  there-
fore considered only if no other options would
be available. She was started on prednisone 80
mg daily for about 1 month and was then slow-
ly tapered to 60 mg daily, partly due to side
effects, especially insomnia. On re-assessment
about 3 months after the start of steroids, the
tumor had responded to steroid treatment as it
was  measured  on  physical  examination  as
3.5ﾥ4  cm  in  size.  The  prednisone  dose  was
subsequently tapered to 50 mg over the course
of 1 month. At that time, progression in tumor
size  was  noted  clinically,  now  measuring
approximately 7ﾥ5 cm, which was confirmed
by repeat MRI.
Because of the progression during steroid
treatment, it was decided to treat the patient
with radiation therapy. It was anticipated that
this could potentially have a high likelihood of
late  toxicity  in  terms  of  radiation-induced
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Figure 2. Coronal T2 Fatsat magnetic resonance imaging during follow-up of patient
after  radiation  treatment.  Note  the  slow  regression  of  the  large  lesion  in  the  right
infratemporal fossa. The 1998 October scan (post-radiation scan) also depicts the pre-
treatment tumor extent, since no regression of tumor size was present yet at that time.
Figure 1. Hypocellular mass composed of bland fibroblasts and myofibroblasts surround-
ed by abundant collagen (A). Perivascular aggregate of small lymphocytes and plasma
cells (B). Scattered spindle cells positive for actin consistent with myofibroblasts (C). [page 34] [Rare Tumors 2012; 4:e12]
retinopathy, given the close proximity of the
tumor to the right orbit and right optical struc-
tures. The patient was informed of this risk
before RT was commenced. In the period of
May-June 1998, a dose of 50 Gy in 25 fractions
was  delivered  with  6  MV  photons  using  a
wedged right anterior-oblique and apical field.
This was followed by another 10 Gy in 5 frac-
tions with modified shielding in order to pro-
tect the right eye, using the same field setup,
resulting in a total dose of 60 Gy in 30 frac-
tions.
Following radiation treatment, the patient
was followed regularly to assess the treatment
response. After treatment, repeat imaging was
performed  on  multiple  occasions.  The  first
post-treatment  MRI  scan  also  depicted  the
pre-treatment tumor extent since on this scan
no reduction in size of the abnormality com-
pared  to  pre-radiotherapy  had  occurred  yet
(Figure 2, 1998 October). Regression of the
size  of  the  lesion  following  radiation  treat-
ment was very slow with little change over the
course  of  the  first  2  years  and  a  gradual
decrease in size over the next years. At the lat-
est  imaging  performed  in  February  2007,
residual soft tissue changes were still present
in  the  infratemporal  fossa,  but  stable  com-
pared to 2003 (Figure 2).
Because of the close proximity of the optical
structures in relation to the radiation fields,
the patient was followed by an ophthalmologist
because of concerns for late optical radiation
toxicity. At her first visit, shortly after the end
of radiation, minimal asymptomatic cataract in
her right eye was seen, which did not require
any  intervention.  After  2  years  of  follow-up,
one cotton wool spot in the macular area was
described,  which  would  be  consistent  with
radiation-induced  early  retinopathy  changes.
This remained stable without any visual dis-
turbances and without any treatment until 8
years after treatment. At that time she present-
ed  with  blurring  and  clouding  of  vision.
Fundoscopy of the right eye showed a macular
hole, and fluorescein angiography subsequent-
ly demonstrated cystoid macular edema with a
few  dot  reddish  lesions  suggestive  of  either
blood or macular aneurysms. The diagnosis of
radiation-induced retinopathy was made and
she was then treated with intravitreal injec-
tions of the anti-VEGF (Vascular Endothelial
Growth  Factor)  agent  bevacizumab  at  six-
weekly intervals. This resulted in an improved
vision. However, at the end of the six weeks
periods, the patient would develop recurrent
blurred  visions,  which  again  would  improve
upon  receiving  the  next  bevacizumab  injec-
tion. This treatment is being continued until
present.
The patient was last seen in the Head and
Neck Clinic in March 2010 with more than 11
years of follow-up after the end of radiation
treatment and there were no signs of disease
progression  and  no  changes  in  her  physical
examination,  compared  to  previous  visits.
Because the clinical situation has remained
unchanged  for  several  years  with  no  suspi-
cious  findings  in  physical  examination,  no
radiological  evaluation  has  been  performed
after 2007. She was still receiving the intravit-
real  injections  with  bevacizumab  and  had  a
stable vision of the affected eye. The vision in
the contralateral eye remained unaffected.
Discussion
This case report describes a patient present-
ing with a locally infiltrating but histological
benign  lesion  that  progressed  after  initial
medical treatment using steroids. The confir-
mation of the benign nature of this lesion, yet
with  a  locally  progressive  behavior  posed  a
dilemma  in  terms  of  clinical  management,
especially given the risk of long-term toxicity
associated with radiation to a target in close
proximity of important normal structures like
the visual system. However, radiation was cho-
sen  over  surgery  because  of  functional  and
cosmetic  concerns  following  an  extensive
resection in this anatomical area. 
The  lesion  was  diagnosed  and  treated  as
TFIL,  which  is  a  rare  benign  disorder  that
mimics a locally aggressive malignancy. It usu-
ally presents clinically as a stony hard lesion
and multiple sites in the head and neck area
may be present at diagnosis. Outside the head
and neck area, TFIL is reported with no more
than  2  case  reports  available  in  the  litera-
ture.7;8 Microscopically, fibrous tissue with the
presence of collagen is seen with an associat-
ed  infiltration  of  lymphocytes,  plasma  cells,
neutrophils and eosinophils. TFIL can invade
vascular  structures  and  muscle10 and  cause
extensive bony destruction,5;10 as well as inva-
sion of the meninges and brain involvement.11
Lesions diagnosed as TFIL in the head and
neck  region  are  believed  to  be  part  of  the
broader  fibrosclerosing  syndrome  that
includes pseudotumour of the orbit or base of
skull,12 Riedel's thyroiditis, sclerosing cholan-
gitis,13 lacrimal gland fibrosis, fibrous parotitis
and mediastinal or retroperitoneal fibrosis. In
fact, in some patients manifestations of the
same disease may occur in multiple organs.
Cheng et al.14 reported on a case of TFIL in the
nasal cavity, who developed Riedel's thyroiditis
subsequently. 
To the best of our knowledge, only 33 cases
of  TFIL  involving  the  head  and  neck  region
have been reported in literature so far, includ-
ing the present case (Table 1).5;9-11;14-25 In TFIL,
medical treatment with steroids has been sug-
gested as first line of management in cases
with TFIL.21 Treatment with surgery is used to
relieve  symptoms  of  compression.  Radiation
therapy is reserved for failures. Information on
the use of radiaton is limited for TFIL5;9;10 in
terms of total dose and fractionation, with only
5 cases reported in literature. In 1 report on 3
cases,  no  details  were  provided  on  the  pre-
scribed radiation dose.10 In two other cases, 50
Gy in 25 fractions was administered to disease
located in the head and neck area.5;9 In IPT of
the base of skull, low dose radiation (20 Gy)
proved to be ineffective with poor disease con-
trol reported in 6 patients.23 In our case, it was
decided to deliver a total dose of 60 Gy. This
was mainly because surgical salvage treatment
after a potential failure following radiation was
considered to be mutilating if surgery would
have to involve resection of (part of) the orbit
and contents.
As apparent from the experience reported in
literature (Table 1), TFIL will in most cases
only  show  a  limited  radiographic  response
after radiation treatment. In 3 cases treated
with radiation therapy from the series of Olsen
et al.,10 a complete regression was observed in
1 patient and stabilization in 2 after radiation.
In a surgically unresectable case reported by
Rice et al.,5tumor size stabilization was report-
ed  as  response  to  treatment.  A  similar
response with stable disease following radia-
tion treatment was seen in a case reported by
Fung et al.9 This pattern of response was con-
firmed in our patient as well. However, if left
untreated  or  unresponsive  to  steroids,  TFIL
may  progress  to  involve  the  base  of  skull,
meninges,  cavernous  sinuses,  brain  and
orbit.11
Given the recent advances in characteriza-
tion  of  benign  soft  tissue  lesions,  we  per-
formed  additional  (immuno-)  histochemial
analysis on this patient’s archived specimen. A
differential  diagnosis  of  this  lesion  was  the
inflammatory  myofibroblastic  tumor  (IMT),26
which has been defined within the category of
IPT  with  distinct  clinical  pathological  and
molecular features.27 IMT is spindle cell prolif-
eration with a variable inflammatory compo-
nent, which mainly occurs in the lung, but has
also  been  reported  in  extrapulmonary  sites,
including  the  mesentery,  genitourinary  sys-
tem, retroperitoneum and pelvis, upper respi-
ratory system, trunk and head and neck area.
The frequency of occurrence in the head and
neck varied from 0% to 29% accross different
case series.28 It involves mainly children and
adolescents.29 IMT often show distinct molecu-
lar  features,  consisting  of  rearrangements
involving  the  ALK  (anaplastic  lymphoma
kinase)  locus  on  chromosome  2p2330 and
approximately 50% of IMTs are positive for ALK
on immunohistochemistry.27
However,  based  on  the  findings  of  the
immunohistochemial analysis, we were unable
to prove that this lesion was a case of IMT and
concluded that the lesion was still to be classi-
fied as TFIL. The clinical characteristics of our
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patient were also in favor of this diagnosis: as
opposed to IMT, tumefactive fibroinflammatory
lesions  tend  to  occur  more  often  in  older
patients (not children and adolescents), often
show a more ill-defined mass entrapping nor-
mal tissue and on pathology TFIL tend to have
more  sclerosis  and  a  patchy,  predominantly
lymphocytic inflammatory infiltrate.27
The etiology of the inflammatory pseudotu-
mors  is  unknown  and  the  pathophysiology
remains  poorly  understood.  An  exaggerated
response to (chronic) infection has been sug-
gested to be a possible mechanism.31 Others
have  suggested  an  autoimmune  reaction
linked to previous (viral) infection.32 However,
evidence for any of these theories is sparse
and inconclusive.
In our patient, the late radiation toxicity in
terms of retinopathy became apparent not until
8  years  after  treatment.  This  highlights  the
need  for  long-term  follow-up  of  toxicity  in
patients  at  risk.  In  the  case  described,  the
retinopathy was due to radiation dose to the
orbital structures, in an era in which conformal
radiation  or  IMRT  (Intensity  Modulated
Radiation  Therapy)  were  not  available.
Nowadays, these types of toxicities may be pre-
vented by means of dose sculpting around the
normal structures. Radiation-induced retinopa-
thy has long been recognized as an irreversible
process leading to loss of vision.33 Recently, the
use of bevacizumab, a humanized anti-VEGF
monoclonal  antibody  has  been  reported  to
result  in  clinical  improvement  of  symptoms
from  radiation-induced  retinopathy.34 as  was
evident from our case.
In conclusion, tumefactive fibroinflammatory
lesion of the head and neck is a rare benign
diagnosis that can present as a locally progres-
sive tumor. In case it is refractory to steroid ther-
apy, radiation can be considered if surgery would
be mutilating, but care has to be paid in order to
prevent (late) radiation-induced toxicity.
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